Inflammatory biomarkers in severe asthma

Current Opinion in Pulmonary Medicine

Volumn 18, Issue 1, 2012, Pages 35-41

  Chung, Kian F ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

asthma phenotypes; biomarkers; exhaled nitric oxide; severe asthma; sputum eosinophils

Indexed keywords

BIOLOGICAL MARKER; CORTICOSTEROID; NITRIC OXIDE;

ASTHMA; CLINICAL FEATURE; DISEASE SEVERITY; EOSINOPHIL COUNT; HUMAN; INFLAMMATION; PHENOTYPE; REVIEW; RISK FACTOR; SPUTUM; TREATMENT RESPONSE;

ASTHMA; BIOLOGICAL MARKERS; CLUSTER ANALYSIS; DISEASE PROGRESSION; EOSINOPHILIA; HUMANS; NITRIC OXIDE; PHENOTYPE; PROGNOSIS; QUESTIONNAIRES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPUTUM;

EID: 83155181425     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32834d09a5     Document Type: Review

References (78)

1. Chung KF, Godard P, Adelroth E, et al. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society. Eur Respir J 1999; 13:1198-1208. (Pubitemid 29288952)
2. Proceedings of the ATS Workshop on Refractory Asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med 2000; 162: 2341-2351.
3. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31:143-178.
4. Bousquet J, Mantzouranis E, Cruz AA, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organisation Consultation on severe asthma. J Allergy Clin Immunol 2010; 126:926-938.
5. Reddel HK, Taylor DR, Bateman ED, et al. An Official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardising endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180:59-99.
6. Bel EH, Sousa A, Fleming L, et al., on behalf of the members of the Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome (U-BIOPRED) Consortium, Consensus Generation. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011; 66:910-917.
7. Moore WC, Bleecker ER, Curran-Everett D, et al. Characterisation of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119:405-413. (Pubitemid 46210080)
8. The ENFUMOSA cross-sectional European Multicentre Study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003; 22:470-477.
9. Bumbacea D, Campbell D, Nguyen L, et al. Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J 2004; 24:122-128. (Pubitemid 39029077)
10. Ten Brinke A, Zwinderman AH, Sterk PJ, et al. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001; 164:744-748. (Pubitemid 32881907)
11. Comhair SA, Ricci KS, Arroliga M, et al. Correlation of systemic superoxide dismutase deficiency to airflow obstruction in asthma. Am J Respir Crit Care Med 2005; 172:306-313. (Pubitemid 41026140)
12. Comhair SA, Gaston BM, Ricci KS, et al. Detrimental effects of environmental tobacco smoke in relation to asthma severity. PLoS One 2011; 6:e18574.
13. Dweik RA, Sorkness RL, Wenzel S, et al. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. Am J Respir Crit Care Med 2010; 181:1033-1041.
14. Gamble C, Talbott E, Youk A, et al. Racial differences in biologic predictors of severe asthma: data from the severe asthma research program. J Allergy Clin Immunol 2010; 126:1149-1156.
15. Liu L, Teague WG, Erzurum S, et al. Determinants of exhaled breath condensate pH in a large population with asthma. Chest 2011; 139:328-336.
16. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med 2010; 181:315-323.
17. Sorkness RL, Bleecker ER, Busse WW, et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol 2008; 104:394-403. (Pubitemid 351231486)
18. Wenzel SE, Balzar S, Ampleford E, et al. IL4R Alpha mutations are associated with asthma exacerbations and mast cell/IgE expression. Am J Respir Crit Care Med 2007; 175:570-576. (Pubitemid 46438941)
19. Li X, Howard TD, Moore WC, et al. Importance of hedgehog interacting protein and other lung function genes in asthma. J Allergy Clin Immunol 2011; 127:1457-1465.
20. Holguin F, Bleecker ER, Busse WW, et al. Obesity and asthma: an association modified by age of asthma onset. J Allergy Clin Immunol 2011; 127:1486-1493.
21. Aysola RS, Hoffman EA, Gierada D, et al. Airway remodeling measured by multi-detector CT is increased in severe asthma and correlates with pathology. Chest 2008; 134:1183-1191.
22. Hastie AT, Moore WC, Meyers DA, et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol 2010; 125:1028-1036.
23. Planaguma A, Kazani S, Marigowda G, et al. Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am J Respir Crit Care Med 2008; 178:574-582.
24. Brasier AR, Victor S, Ju H, et al. Predicting intermediate phenotypes in asthma using bronchoalveolar lavage-derived cytokines. Clin Transl Sci 2010; 3:147-157.
25. Bhavsar P, Hew M, Khorasani N, et al. Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma. Thorax 2008; 63:784-790.
26. Hew M, Bhavsar P, Torrego A, et al. Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am J Respir Crit Care Med 2006; 174:134-141. (Pubitemid 44015386)
27. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178:218-224.
28. Shannon J, Ernst P, Yamauchi Y, et al. Differences in airway cytokine profile in severe asthma compared to moderate asthma. Chest 2008; 133:420-426. (Pubitemid 351272400)
29. Brims FJ, Chauhan AJ, Higgins B, Shute JK. Coagulation factors in the airways in moderate and severe asthma and the effect of inhaled steroids. Thorax 2009; 64:1037-1043.
30. Macedo P, Hew M, Torrego A, et al. Inflammatory biomarkers in airways of patients with severe asthma compared with non-severe asthma. Clin Exp Allergy 2009; 39:1668-1676.
31. Jatakanon A, Uasuf C, Maziak W, et al. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999; 160 (5 Pt 1):1532-1539.
32. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715-1721. (Pubitemid 35447900)
33. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973-984.
34. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisonedependent asthma with sputum eosinophilia. N Engl J Med 2009; 360:985-993.
35. Kikuchi S, Nagata M, Kikuchi I, et al. Association between neutrophilic and eosinophilic inflammation in patients with severe persistent asthma. Int Arch Allergy Immunol 2005; 137 (Suppl 1):7-11. (Pubitemid 40868767)
36. Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001; 119:1329-1336. (Pubitemid 32686012)
37. Cowan DC, Cowan JO, Palmay R, et al. Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax 2010; 65:384-390.
38. Nguyen LT, Lim S, Oates T, Chung KF. Increase in airway neutrophils after oral but not inhaled corticosteroid therapy in mild asthma. Respir Med 2005; 99:200-207. (Pubitemid 40104275)
39. Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils: separation of survival and activation outcomes. J Immunol 1995; 154:4719-4725.
40. Vachier I, Bonnans C, Chavis C, et al. Severe asthma is associated with a loss of lx4, an endogenous anti-inflammatory compound. J Allergy Clin Immunol 2005; 115:55-60. (Pubitemid 40075421)
41. Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. PLoS One 2010; 5:e8578.
42. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160:1001-1008. (Pubitemid 29442043)
43. Al Samri MT, Benedetti A, Prefontaine D, et al. Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy: a prospective study using multiple samples. J Allergy Clin Immunol 2010; 125:1161-1163.
44. Van Veen IH, Ten Brinke A, Gauw SA, et al. Consistency of sputum eosinophilia in difficult-to-treat asthma: a 5-year follow-up study. J Allergy Clin Immunol 2009; 124: 615-617.
45. Shaw DE, Berry MA, Thomas M, et al. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med 2007; 176:231-237. (Pubitemid 47195872)
46. Pijnenburg MW, Bakker EM, Hop WC, De Jongste JC. Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. Am J Respir Crit Care Med 2005; 172:831-836. (Pubitemid 41369065)
47. Smith AD, Cowan JO, Brassett KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352:2163-2173.
48. Stirling RG, Kharitonov SA, Campbell D, et al. Increase in exhaled nitric oxide levels in patients with difficult asthma and correlation with symptoms and disease severity despite treatment with oral and inhaled corticosteroids. asthma and allergy group. Thorax 1998; 53:1030-1034. (Pubitemid 28567003)
49. Silkoff PE, Lent AM, Busacker AA, et al. Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma. J Allergy Clin Immunol 2005; 116:1249-1255. (Pubitemid 41740931)
50. Lara A, Khatri SB, Wang Z, et al. Alterations of the arginine metabolome in asthma. Am J Respir Crit Care Med 2008; 178:673-681.
51. Nair P, Kjarsgaard M, Armstrong S, et al. Nitric oxide in exhaled breath is poorly correlated to sputum eosinophils in patients with prednisone-dependent asthma. J Allergy Clin Immunol 2010; 126:404-406.
52. Van Veen IH, Ten Brinke A, Sterk PJ, et al. Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma. Eur Respir J 2008; 32:344-349.
53. Gaston B. The biochemistry of asthma. Biochim Biophys Acta 2011 (in press).
54. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180:388-395.
55. Fitzpatrick AM, Higgins M, Holguin F, et al. The molecular phenotype of severe asthma in children. J Allergy Clin Immunol 2010; 125:851-857.
56. Moffatt MF, Gut IG, Demenais F, et al. Consortium-based genomewide association study of asthma. N Engl J Med 2010; 363:1211-1221.
57. Cohen L, Tarsi EX, Ramkumar J, et al. Epithelial cell proliferation contributes to airway remodeling in severe asthma. Am J Respir Crit Care Med 2007; 176: 138-145. (Pubitemid 47057849)
58. Pegorier S, Arouche N, Dombret MC, et al. Augmented epithelial endothelin-1 expression in refractory asthma. J Allergy Clin Immunol 2007; 120:1301-1307. (Pubitemid 350216607)
59. Thomas B, Rutman A, Hirst RA, et al. Ciliary dysfunction and ultrastructural abnormalities are features of severe asthma. J Allergy Clin Immunol 2010; 126:722-729.
60. Pepe C, Foley S, Shannon J, et al. Differences in airway remodelling between subjects with severe and moderate asthma. J Allergy Clin Immunol 2005; 116:544-549. (Pubitemid 41267126)
61. Kaminska M, Foley S, Maghni K, et al. Airway remodeling in subjects with severe asthma with or without chronic persistent airflow obstruction. J Allergy Clin Immunol 2009; 124:45-51.
62. Benayoun L, Druilhe A, Dombret MC, et al. Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med 2003; 167:1360-1368. (Pubitemid 36609720)
63. Bourdin A, Neveu D, Vachier I, et al. Specificity of basement membrane thickening in severe asthma. J Allergy Clin Immunol 2007; 119:1367-1374. (Pubitemid 46855858)
64. Bhavsar PK, Levy BD, Hew MJ, et al. Corticosteroid suppression of lipoxin a4 and leukotriene b4 from alveolar macrophages in severe asthma. Respir Res 2010; 11:71.
65. Huynh ML, Malcolm KC, Kotaru C, et al. Defective apoptotic cell phagocytosis attenuates prostaglandin E2 and 15-hydroxyeicosatetraenoic acid in severe asthma alveolar macrophages. Am J Respir Crit Care Med 2005; 172:972-979. (Pubitemid 41476533)
66. Fitzpatrick AM, Holguin F, Teague WG, et al. Alveolar macrophage phagocytosis is impaired in children with poorly controlled asthma. J Allergy Clin Immunol 2008; 121: 1372-1378.
67. Fitzpatrick AM, Teague WG, Holguin F, et al. Airway glutathione homeostasis is altered in children with severe asthma: evidence for oxidant stress. J Allergy Clin Immunol 2009; 123:146-152.
68. Chung KF, Marwick JA. Molecular mechanisms of oxidative stress in airways and lungs with reference to asthma and chronic obstructive pulmonary disease. Ann N Y Acad Sci 2010; 1203:85-91.
69. Bhavsar P, Khorasani N, Hew M, et al. Effect of P38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma. Eur Respir J 2010; 35:750-756.
70. Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008; 177:148-155.
71. Adcock IM, Ford PA, Bhavsar P, et al. Steroid resistance in asthma: mechanisms and treatment options. Curr Allergy Asthma Rep 2008; 8:171-178. (Pubitemid 351524105)
72. Chung KF. P38 Mitogen-activated protein kinase pathways in asthma and COPD. Chest 2011; 139:1470-1479.
73. Hakonarson H, Bjornsdottir US, Halapi E, et al. Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients. Proc Natl Acad Sci USA 2005; 102:14789-14794. (Pubitemid 41457134)
74. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358:2107-2116. (Pubitemid 351679597)
75. Camargo A, Azuaje F. Identification of dilated cardiomyopathy signature genes through gene expression and network data integration. Genomics 2008; 92:404-413.
76. Manolio TA, Bailey-Wilson JE, Collins FS. Genes, environment and the value of prospective cohort studies. Nat Rev Genet 2006; 7:812-820. (Pubitemid 44413225)
77. Bousquet J, Anto JM, Sterk PJ, et al. Systems medicine and integrated care to combat chronic noncommunicable diseases. Genome Med 2011; 3:43.
78. Auffray C, Adcock IM, Chung KF, et al. An integrative systems biology approach for understanding of pulmonary diseases. Chest 2010; 137:1-7.